Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

682
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
682
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

236
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
236
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

3.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.0K
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

155
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
155
Human Genetics01:28

Human Genetics

1.5K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.5K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

166
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
166

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hydrocodone vs Oxycodone and Postoperative Pain and Opioid Use in Joint Arthroplasty.

JAMA network open·2026
Same author

Creation of a Merged Harmonized Large Database of Subject-Level Data from Acute Secondary Prevention Studies in Minor Non-Cardioembolic Stroke or TIA.

International journal of cerebrovascular disease and stroke·2026
Same author

CYP2D6 phenotype and post-surgical pain control with hydrocodone and oxycodone.

Frontiers in pharmacology·2026
Same author

Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial.

JAMA network open·2026
Same author

The Future of Clinical Translational Pharmacology.

Clinical pharmacology and therapeutics·2026
Same author

Genetic Testing for APOL1 in Adults With Hypertension: The GUARDD-US Randomized Clinical Trial.

JAMA network open·2026

Related Experiment Video

Updated: Jan 17, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.1K

Pharmacogenetic Testing - Evidence, Challenges, and Pathways to Adoption.

Nihal El Rouby1,2, Julie A Johnson3,4

  • 1Division of Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati.

NEJM Evidence
|September 23, 2025
PubMed
Summary

Clinical pharmacogenetic testing uses genetics to guide drug selection and dosing for better patient outcomes. Despite increased use, challenges in clinician confidence, reimbursement, and guideline integration persist, with future opportunities in broader testing and EHR integration.

More Related Videos

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.3K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.6K

Related Experiment Videos

Last Updated: Jan 17, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.1K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.3K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.6K

Area of Science:

  • Pharmacogenomics and Precision Medicine
  • Clinical Pharmacology
  • Genetics and Drug Response

Background:

  • Genetics significantly influences individual responses to medications.
  • Clinical pharmacogenetic testing is increasingly used to personalize drug therapy.
  • Numerous pharmacogenetic associations have been identified across various medical specialties.

Purpose of the Study:

  • To review the current state of clinical pharmacogenetics.
  • To identify facilitators and barriers to its adoption.
  • To outline future opportunities for expanding its use.

Main Methods:

  • Review of recent scientific literature and clinical practice trends.
  • Analysis of factors influencing the integration of pharmacogenetics into healthcare.
  • Identification of challenges and future directions.

Main Results:

  • Pharmacogenetic testing has seen increased uptake and public interest.
  • Key challenges include clinician confidence, reimbursement, data requirements, and guideline inclusion.
  • Opportunities exist for multigene panels, clinician training, EHR integration, and outcomes data.

Conclusions:

  • Clinical pharmacogenetics offers significant potential for optimizing drug therapy.
  • Addressing current barriers is crucial for wider implementation.
  • Future advancements will likely involve technological integration and evidence generation.